etranacogene dezaparvovec

CSL-UniQure Hemophilia B Gene Therapy Scores Priority Review
BioSpace
Tue, 05/24/22 - 04:34 pm
CSL Behring
uniQure
hemophilia B
gene therapy
FDA
priority review
etranacogene dezaparvovec
Uniqure's Hemophilia B Gene Therapy Unlikely To Be Cause Of Liver Cancer Reported In One Patient
Benzinga
Mon, 03/29/21 - 10:36 am
uniQure
gene therapy
hemophilia B
etranacogene dezaparvovec
clinical trials
UniQure/CSL hit by FDA clinical hold for hem B gene therapy program after liver cancer find
Fierce Biotech
Mon, 12/21/20 - 11:09 am
uniQure
CSL
FDA
clinical trials
hemophilia B
gene therapy
etranacogene dezaparvovec
UniQure out-licenses hemophilia B gene therapy in deal valued up to ~$2.1B
Seeking Alpha
Wed, 06/24/20 - 11:29 pm
uniQure
CSL
hemophilia B
etranacogene dezaparvovec